Join to access to all OVN content. Join for Free
COMP: How HR Determines Compensation and Titles for Job Offers
MSL job negotiation HR compensation strategies job offer negotiation tips internal equity in job offers sign-on bonuses in employment

COMP: How HR Determines Compensation and Titles for Job Offers


Share This Article


Summary

In this episode, Chris Castin joins Tom Caravela to delve into the intricacies of compensation and negotiation processes for MSL roles. They explore how to prepare for job offer negotiations while emphasizing the importance of transparency and the risks of over-negotiating. Chris provides insights into HR perspectives and how offers are determined using formulas and data, highlighting the significance of internal equity. The discussion covers the role of job titles, leveling, and the impact of experience on role effectiveness. They also analyze written job offers, discuss sign-on bonuses, and offer advice on responding to offers with effective negotiation strategies. The episode concludes with practical advice for MSLs navigating job offers.

My guest today is Chris Castin, Senior Director, Talent Acquisition NKARTA Therapeutics and we discuss how HR departments determine compensation and titles for job offers

Chris shares…

👉 The HR formula for determining job offers
👉 What you need to know to negotiate an offer
👉 What information is expected in advance of the job offer
👉 How and why sign-on bonuses are used
👉 The way HR determines titles and leveling

Click for Source
MSL job negotiation, HR compensation strategies, job offer negotiation tips, internal equity in job offers, sign-on bonuses in employment

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How to Negotiate a Job Offer
Partner Avatar MSL Talk: Tom Caravela

How to Negotiate a Job Offer

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Article
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
OVN Avatar J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Explore OVN